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Abstract
Venous ulcers are the most severe manifestation of post-thrombotic syndrome (PTS). We have previously demonstrated 
that formation of compact fibrin clots resistant to lysis is observed in patients following deep-vein thrombosis (DVT) who 
developed PTS. The current study investigated whether unfavourable fibrin clot properties can predict post-thrombotic 
venous ulcers. In a cohort study on 186 consecutive patients following DVT, we determined plasma fibrin clot characteristics, 
including clot permeability and lysability, inflammatory markers, thrombin generation, fibrinolysis proteins at 3 months since 
the index event. Occurrence of PTS and venous ulcers was recorded during follow-up (median, 53; range 24 to 76 months). 
Fifty-seven DVT patients (30.6%) developed PTS, including 12 subjects (6.45%) with a venous ulcer (4 individuals with 
recurrent ulcers). Patients who developed ulcers compared with the remainder had at enrolment 13.0% lower clot permeability 
 (Ks), 17.4% longer clot lysis time (CLT), 13.1% longer lag phase of clot formation, and 5.0% higher maximum absorbance, 
with no difference in fibrinogen, C-reactive protein, and thrombin generation. The baseline prothrombotic fibrin clot phe-
notype  (Ks ≤ 6.5 × 10−9 cm2 and CLT > 100 min) was associated with a higher risk of ulcers [hazard ratio (HR), 5.37; 95% 
confidence interval (CI), 1.3–21.5]. A multivariate model adjusted for age, sex, and fibrinogen showed that independent 
predictors of the ulcer occurrence were body mass index (HR 1.53; 95% CI 1.30–1.86), CLT (HR 1.43; 95% CI 1.04–2.05), 
and α2-antiplasmin (HR 0.95; 95% CI 0.90–0.99). This study suggests that formation of denser fibrin clots with impaired 
fibrinolysis predisposes to post-thrombotic venous ulcers.
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Highlights
• Post-thrombotic syndrome (PTS) is a common sequela 
of deep-vein thrombosis (DVT).
• Prothrombotic clot properties, including dense fibrin net-
works resistant to lysis, have been observed in patients 
with DVT who developed PTS during follow-up.
• The most severe manifestation of PTS is a venous ulcer. 
The known risk factors of venous ulcer formation are 
older age, obesity and the presence of reflux in deep 
veins of the lower extremity.
• Patients who develop venous ulcers during follow-up 
tend to display a specific fibrin clot phenotype, includ-
ing reduced clot permeability and susceptibility to lysis, 
at 3 months since the index DVT.
• Prolonged clot lysis time (CLT), lower α2-antiplasmin 
and elevated body mass index were identified as inde-
pendent predictors of the post-thrombotic venous ulcer. It 
can be speculated that measurement of clot permeability 
and CLT might be useful in identifying DVT patients at 
high risk of post-thrombotic ulcers.
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Introduction
A venous ulcer is a debilitating manifestation of severe post-
thrombotic syndrome (PTS) following deep-vein thrombosis 
(DVT). PTS develops in 20% to 50% of DVT patients, and 
severe PTS, including venous ulcers, develops in 5% to 10% 
[1]. The prevalence of venous ulcers has been estimated to 
range between 0.1 and 2% [2, 3]. Management of venous ulcers 
is a challenge for a patient and healthcare system [4], given 
their recurrences in 26–69% of patients within 12 months [5].
Venous ulcers tend to form in the gaiter area of the leg, 
shallow, surrounded by oedematous tissue and dilated veins 
[6]. The venous leg ulcer has been postulated to arise from a 
chronic inflammatory injury secondary to sustained venous 
hypertension [7]. The development of venous ulcers might 
result from primary venous valvular reflux or be secondary 
to previous DVT event [4].
The principal risk factors for PTS are anatomically extensive 
DVT, failure of vein recanalization, recurrent ipsilateral DVT, 
persistent leg symptoms 1 month after acute DVT, obesity, and 
older age [1]. Risk factors for ulcers involve age [8], presence of 
the reflux in the deep veins [9], high body mass index (BMI), 
and low physical activity [10], as well as potentially male sex, 
smoking, diabetes, peripheral arterial disease and leg injury 
[11]. Anticoagulant therapy and use of compression stockings 
do not decrease the risk of ulcer development [12].
Blood coagulation eventually results in formation of fibrin 
clots and their characteristics, reflected by its density and lys-
ability, differ significantly among individuals in association 
with various genetic and environmental factors [13]. It has 
been shown that clots composed of thin and highly branched 
fibrin fibres predispose to arterial and venous thromboembolic 
events and might have a predictive value in terms of recurrent 
episodes [14–16]. In 2016 we found that the prothrombotic 
plasma clot phenotype detected about 3 months since acute 
DVT is associated with PTS during follow-up [17]. More 
compact fibrin clot phenotype was also associated with higher 
plasma D-dimer, C-reactive protein (CRP) and thrombin-acti-
vatable fibrinolysis inhibitor (TAFI). However, none of those 
patients had venous ulcers.
We hypothesised that the unfavourable fibrin clot pheno-
type increases the risk of developing venous ulcers in DVT 
patients. For this reason, we performed a cohort study among 
DVT patients with a long-term follow-up to assess association 
between fibrin properties and venous ulcers.
Patients and methods
We studied 197 patients with documented first-ever DVT. 
Patient characteristics were presented in detail previously 
[17]. They were referred to an outpatient clinic for fur-
ther diagnostic work-up between October 2008 and June 
2010. The diagnosis of DVT was established by a positive 
finding on colour duplex sonography. The diagnosis of 
pulmonary embolism was based on the presence of typical 
symptoms and positive results of high-resolution spiral 
computed tomography. A venous thromboembolism (VTE) 
episode was defined as unprovoked if the patient had no 
history of cancer, surgery requiring general anaesthesia, 
major trauma, a plaster cast or hospitalization within 
the last month, or pregnancy or delivery within the last 
3 months. Patients were treated with heparin followed by 
vitamin K antagonist (VKA).
Laboratory investigations
Blood samples were collected after fasting from individ-
uals after about 3 months of anticoagulant therapy fol-
lowing the DVT diagnosis. Prior to the testing, patients 
receiving VKA treatment were switched to heparin for 
10–14 days. 12 h following the last injection, when the 
INR was < 1.2, samples were drawn. Detailed methodol-
ogy was presented previously [17]. To evaluate lipid pro-
files, complete blood count, glucose, creatinine and INR, 
routine laboratory techniques were used. Fibrinogen was 
determined using the Clauss assay. High-sensitivity CRP 
was measured by immunoturbidimetry (Roche Diagnos-
tics, Mannheim, Germany). Plasma D-dimer was meas-
ured with the Innovance D-dimer assay (Siemens, Mar-
burg, Germany). Plasminogen activator inhibitor-1 (PAI-1) 
antigen (American Diagnostica, Stamford, CT, USA) was 
measured using an ELISA, while α2-antiplasmin (α2AP) 
and plasminogen were measured by chromogenic assays 
(STA Stachrom antiplasmin and STA Stachrom plasmino-
gen, Diagnostica Stago, Asnières, France). Plasma-acti-
vated TAFI was measured by a chromogenic assay using 
the  ACTICHROME® Plasma TAFI Activity Kit (Ameri-
can Diagnostica). We measured activated and inactivated 
TAFI (TAFIa/ai) antigen in plasma using a commercially 
available ELISA kit (Imubind TAFIa/ai antigen ELISA; 
American Diagnostica) and results were expressed as per-
centage of pooled plasma from healthy volunteers. Plasma 
FVIII activity was determined using a one-stage clotting 
assay (Siemens).
To evaluate clot properties and thrombin generation, 
venous blood samples (vol/vol, 9:1 of 3.2% trisodium cit-
rate) were centrifuged at 2000×g for 10 min within 30 min 
of the draw, and the supernatant was aliquoted and stored 
at – 80  °C until analysis. All measurements were per-
formed by technicians blinded to the origin of the samples.
Plasma thrombogenic potential was assessed with cali-
brated automated thrombography (CAT) (Thrombinoscope 
BV, Maastricht, the Netherlands) in a 96-well plates fluo-
rometer (Ascent Reader, Thermolab Systems OY, Helsinki, 
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Finland) [18]. Fibrin clot permeation was determined by 
means of a pressure-driven system [19, 20]. Based on the 
volume of a buffer flowing through a clot, permeability coef-
ficient  (Ks) was calculated. Lysability of clots was deter-
mined by measuring clot lysis time (CLT), defined as the 
time from the midpoint of the clear-to-maximum-turbid tran-
sition to the midpoint of the maximum-turbid-to-clear tran-
sition, and by measuring the maximum rate of increase in 
D-dimer levels (D-Drate) and maximum D-dimer concentra-
tions (D–Dmax) during clot perfusion with rtPA [19, 21, 22].
To determine turbidity measurements, plasma citrated 
samples were mixed with human thrombin (Sigma-Aldrich) 
and  CaCl2 and absorbance was read at 405 nm as described 
[23].
Genotyping
The FV Leiden, prothrombin 20210A, FXIII Val34Leu and 
α-fibrinogen Thr312Ala polymorphisms were determined 
as described [19].
Follow‑up
The patients completed a follow-up period of a minimum 
of 24 months since enrolment. At their last visit they were 
assessed using a Villalta scale in order to determine the pres-
ence and severity of PTS. Patients were diagnosed with PTS 
if the Villalta score was at least 5. A score of 5–9 points was 
categorised as mild, 10–14 as moderate, and 15 and more as 
severe manifestation of the disease [24].
Every 6 months participants were examined at the clinic 
in terms of the presence of a venous ulcer. In individuals 
presented with an ulcer additional data on time of its appear-
ance, healing and recurrence were collected. The patients 
were examined in terms of the recurrence of DVT during 
follow-up. Use of compression stockings and anticoagula-
tion treatment were also monitored.
Statistical analysis
The study was powered to have a 80% chance of detect-
ing a 16% difference in CLT using a one-sided P value of 
0.025, based on the values of clot lysis time in the previous 
study [17]. In order to demonstrate such a difference, or a 
greater one, in total 180 subjects were required, including 
12 patients with ulceration.
Categorical variables are presented as numbers and 
percentages. Continuous variables are expressed as 
mean ± standard deviation (SD) or median and interquar-
tile range (IQR). Normality was assessed by the Shap-
iro–Wilk test. Equality of variances was assessed using the 
Levene’s test. Differences between groups were compared 
using the Student’s or the Welch’s t test depending on the 
equality of variances for normally distributed variables. 
The Mann–Whitney U-test was used for non-normally dis-
tributed continuous variables. Categorical variables were 
compared by the Pearson’s Chi squared test or the Fisher’s 
exact test if 20% of cells had an expected count of < 5. Uni-
variate and multivariate Cox proportional hazard analysis 
was performed to identify independent predictors of the 
outcomes. The multivariate models were fitted using back-
ward stepwise regression. Variables that were associated 
with the occurrence of the outcomes in univariate models 
with a significance level of P < 0.25 were selected for pos-
sible inclusion in the multivariate logistic regression model. 
The log-rank statistic was used to test the differences in the 
outcomes between the groups. Two-sided P-values < 0.05 
were considered statistically significant. All calculations 
were done with  JMP®, Version 14.2.0 (SAS Institute Inc., 
Cary, NC, USA).
Results
Since eleven patients were lost to follow-up, a total of 186 
patients were included in the final analysis. Characteristics 
of the study population were shown in Table 1.
After a median follow-up of 53 months, PTS was diag-
nosed in 57 subjects (30.6%), including 21 cases of mild 
(11.3%), 12 cases of moderate (5.9%) and 24 (12.9%) cases 
of severe PTS. Venous ulcers occurred in 12 (6.45%) indi-
viduals. The presence of an ulcer on the lower extremity 
persisted for 6 to 17 months (10 months, median). In one 
case the ulcer remained unhealed until the end of obser-
vation period. Four patients (2.15%) suffered from recur-
rent ulcers. Individuals who developed ulcers were more 
frequently obese compared to the remainder, with no other 
demographics and clinical intergroup differences (Table 1). 
Compression therapy and anticoagulant therapy were 
reported by most patients in the ulcer group compared with 
the non-ulcer group (Table 1).
Analysis of haemostatic markers showed that the occur-
rence of ulcers was associated with lower concentration α2-
antiplasmin and higher TAFI activity at enrolment (Table 1). 
There were no intergroup differences in fibrinogen, CRP and 
thrombin generation. The four genetic polymorphisms tested 
were similarly distributed in the two groups (Table 1).
As shown in Table 2, at 3 months since the DVT diag-
nosis,  Ks was 13.0% lower in the patients who developed 
venous ulcers during follow-up as compared to the remain-
der, while CLT was 17.4% longer in this group. Further-
more, we observed 13.1% longer lag phase and 5% greater 
ΔAbs in the ulcer group compared with the non-ulcer 
group (Table 2). Both D–Dmax and D-Drate values showed 
no intergroup differences. The so-called prothrombotic 
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phenotype of the fibrin clot, defined as the lower quar-
tile of  Ks (≤ 6.5 × 10−9 cm2) and the top quartile of CLT 
(> 100 min), was associated with a 5.37-fold [95% confi-
dence interval (CI) 1.3–21.5] higher risk of venous ulcers 
in patients with DVT during follow-up.
Univariate analysis showed that BMI, recurrent VTE, 
using of compression prior to ulcer, anticoagulation, CRP, 
ΔAbs, CLT and TAFI activity were positively associated 
with the risk of a venous leg ulcer, and shorter lag phase, 
 Ks, and α2-antiplasmin increased the risk of venous ulcer 
occurrence (data not shown). A multivariate model showed 
that CLT, BMI and α2-antiplasmin are predictors of the ulcer 
occurrence (Supplementary Table S1).
Table 1  Baseline patient characteristics
Data are shown as mean ± SD or a median (interquartile range) or number (percentage)
VTE venous thromboembolism, PTS post-thrombotic syndrome, DVT deep vein thrombosis, PE pulmonary embolism, INR international normal-
ized ratio, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, CRP C-reactive protein, 
PAI-1 plasminogen activator inhibitor-1, and TAFI thrombin-activatable fibrinolysis inhibitor
Variables Total cohort (n = 186) Patients with venous ulcer 
(n = 12)
Patients free of venous ulcer 
(n = 174)
P
Age (years) 45 (33–54.25) 47.5 (39.5–60.75) 45 (32–53.25) 0.147
Male [n (%)] 101 (54.3) 4 (33.3) 97 (55.8) 0.132
Body mass index (kg/m2) 26.85 (24.9–29.2) 33.75 (30.6–36.05) 26.65 (24.88–28.93) < 0.001
Obesity [n (%)] 28 (15.05) 10 (83.3) 18 (10.3) < 0.001
Active smoking [n (%)] 73 (39.3) 3 (25) 70 (40.2) 0.371
Family history of VTE [n (%)] 28 (15.1) 2 (16.7) 26 (14.9) 1.000
Clinical variables [n (%)]
 Post-Trauma VTE 38 (20.4) 0 (0) 38 (21.8) 0.130
 Unprovoked VTE 91 (48.9) 7 (58.3) 84 (48.3) 0.500
 DVT alone 57 (30.7) 3 (25) 54 (31) 0.758
 PE + DVT 129 (69.3) 9 (75) 120 (69)
 Proximal DVT 138 (74.2) 11 (91.7) 127 (73) 0.192
 Anticoagulant therapy 44 (23.7) 10 (83.3) 34 (19.5) < 0.001
 Compression therapy 22 (11.8) 9 (75) 13 (7.5) < 0.001
Laboratory investigations at enrolment
 INR 0.98 (0.9–1.05) 1.01 (0.97–1.07) 0.98 (0.90–1.05) 0.097
 D-dimer (ng/mL) 214 (160–283) 241 (213–265) 211 (158–287) 0.138
 Fibrinogen (g/L) 2.98 (2.48–3.87) 3.03 (2.67–4.05) 2.98 (2.45–3.87) 0.544
 Creatinine (μmol/L) 71.18 ± 13.51 70.92 ± 11.05 71.20 ± 13.69 0.944
 Glucose (mmol/L) 4.9 (4.58–5.3) 5.10 (4.85–5.48) 4.90 (4.51–5.30) 0.174
 Triglycerides (mmol/L) 1.16 (0.71–1.72) 1.34 (0.90–1.68) 1.15 (0.71-1.72) 0.754
 TC (mmol/L) 5.05 (4.2–5.78) 4.91 (4.43–5.93) 5.07 (4.19–5.78) 0.831
 LDL-C (mmol/L) 3.04 ± 0.86 3.09 ± 0.82 3.04 ± 0.87 0.845
 HDL-C (mmol/L) 1.40 (1.14–1.69) 1.32 (0.99–1.66) 1.40 (1.14–1.71) 0.326
 CRP (mg/L) 1.70 (1.02–2.34) 2.64 (1.16–7.45) 1.61 (1.02–2.31) 0.059
 Peak thrombin, nM 233 (198–305) 230 (188–307) 233 (199–305) 0.544
 Factor VIII (%) 124 (103–142) 120 (111–143) 124 (102–142) 0.912
 PAI-1 (ng/mL) 12.10 (8.79–18.05) 9.64 (8.27–17.65) 12.25 (8.88–18.35) 0.353
 TAFI activity (µg/mL) 25.55 (20.20–30.30) 31.41 (26.12–39.67) 25.15 (20.14–29.97) 0.004
 TAFI antigen (%) 100 (89–110) 108 (96–116) 100 (89–110) 0.066
 Plasminogen (%) 107 (97–120) 106 (91–119) 107 (98–120) 0.392
 α2-antiplasmin (%) 103 (96–116) 97 (90–103) 104 (97–116) 0.022
Genetic polymorphisms [n (%)]
 Factor V Leiden 24 (12.9) 1 (8.3) 23 (13.2) 1.00
 Prothrombin 20210A 7 (3.8) 0 (0) 7 (4) 1.00
 Factor XIII Val34Leu 84 (45.2) 6 (50) 78 (44.8) 0.728
 α-fibrinogen Thr312Ala 82 (44.1) 8 (66.7) 74 (42.5) 0.103
607Prothrombotic clot properties can predict venous ulcers in patients following deep vein…
1 3
Patients who developed PTS presented in Supplementary 
Table S2 were characterised by a 10% lower  Ks, 14% longer 
CLT, 9% shorter lag phase, and 4% higher ΔAbs, all typical 
of the prothrombotic fibrin clot phenotype (Supplementary 
Table S3).
Discussion
To our knowledge, this study is the first to show association 
of the plasma fibrin clot phenotype and venous ulcers among 
DVT patients. We found that denser fibrin clot formation and 
reduced susceptibility to lysis not only predispose to PTS, 
which is in line with our previous study with a shorter fol-
low-up of 12 months [17], but also significantly increase the 
risk of a post-thrombotic venous ulcer. Our findings suggest 
that unfavourable fibrin clot properties may have a predictive 
value in terms of venous ulcers.
Analysis of several proteins involved in fibrinolysis in the 
context of post-thrombotic leg ulcers provided additional 
interesting observations. We noted that DVT patients with 
venous ulcers had higher baseline TAFI activity accompa-
nied by lower α2-antiplasmin compared with the remaining 
subjects, without any differences in PAI-1 or plasminogen. 
The observation on TAFI is consistent with our previous 
study, where hypofibrinolysis was associated with higher 
TAFI activity in PTS patients [17]. The current finding sup-
ports involvement of elevated TAFI activity in PTS. Surpris-
ingly, in individuals in the ulcer group we observed lower 
α2-antiplasmin levels, but all within the reference range, 
without any difference in this parameter related to the pres-
ence or absence of PTS. This key fibrinolysis inhibitor [25] 
accounts for about 90% of plasmin inhibition in vivo [26]. 
Since the resistance of thrombi to plasmin digestion depends 
primarily on the amount of α2AP incorporated within fibrin, 
lower antifibrinolytic antiplasmin, though linearly not cor-
related to CLT, might suggest that increased, not impaired, 
fibrinolysis enhances the post-thrombotic ulcer formation. 
However, we found that prolonged CLT is associated with 
this complication of DVT, therefore it is unlikely that anti-
plasmin-mediated impact on global efficiency of fibrinolysis 
explains the protective effect of lower α2AP on ulcer forma-
tion. Lower antiplasmin could indicate changes in a physi-
ological ratio of two forms of this protein [27]. Antiplasmin-
cleaving enzyme (APCE) cleaves Met-α2AP to Asn-α2AP, 
which is more efficiently incorporated into fibrin and makes 
it resistant to plasmin digestion. Another potential factor 
affecting the antiplasmin could be α2AP posttranslational 
modifications such as oxidation that may modulate the pro-
tein’s function [28]. Mechanisms underlying the role of 
antiplasmin in the context of post-thrombotic ulcers require 
further research. We cannot exclude that modulation of anti-
plasmin activity might prevent venous ulcer formation.
Looking at several demographic and clinical factors and 
their associations with post-thrombotic ulcers, we identified 
obesity as the strongest predisposing factor, which agrees 
with several papers [9, 10]. Galanaud et al. found that the 
male sex increases the risk of ulcers after VTE at 1 year 
only, whereas after 2 or 3 years of follow-up this association 
was no longer significant [12]. We did not observe a higher 
proportion of males in the ulcer group during a few years 
since DVT, which is similar to that study. Since diabetic 
patients had been excluded from our study due to prothrom-
botic clot alterations observed commonly in diabetes [17, 
29], the impact of this disease on post-thrombotic ulcers was 
not evaluated in the present study. Anticoagulant therapy 
and the use of compression stockings did not reduce the risk 
of venous ulceration [12], which agrees with our findings.
We found higher CRP levels of borderline statistical sig-
nificance in the ulcer group, while fibrinogen concentrations 
were similar. Previous studies demonstrated that elevated 
plasma levels of inflammatory biomarkers, including CRP, 
were associated with PTS [30, 31]. This study supports the 
view that elevated CRP is not related to the risk of leg ulcer-
ation. Nonetheless, increased CRP levels in patients with 
ulcers might indicate the presence of infection in affected tis-
sues [32]. On the other hand, we confirmed that the presence 
of PTS has been linked to systemic inflammation. We did 
Table 2  Comparison of fibrin 
clot properties
Values are given as mean ± SD or a median (interquartile range)
Ks indicates permeability coefficient; CLT clot lysis time, ΔAbs maximum absorbance, D-Dmax maximum 
D-dimer levels in the lysis assay, and D-Drate maximum rate of increase in D-dimer levels in the lysis assay
Variable Total cohort (n = 186) Patients with venous 
ulcer (n = 12)
Patients free of 
venous ulcer (n = 174)
P
Ks,  10−9 cm2 7.45 ± 1.27 6.53 ± 0.45 7.51 ± 1.28 < 0.001
CLT (min) 88 (72–100) 101 (88–114) 86 (72–99) 0.007
Lag phase (s) 41 (37–46) 36.5 (35–39.75) 42 (38–46) 0.003
ΔAbs (405 nm) 0.81 (0.75–0.86) 0.84 (0.81–0.9) 0.8 (0.74–0.86) 0.03
D-Dmax (mg/L) 3.99 (3.60–4.39) 3.68 (3.59–3.99) 4.07 (3.6–4.39) 0.132
D-Drate (mg/L/min) 0.072 ± 0.008 0.072 ± 0.009 0.072 ± 0.008 0.68
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not observe any impact of heightened thrombin generation 
at baseline on development of venous ulcers in follow-up, 
therefore elevated thrombin, the well-known factor leading 
to more compact clot network formation [33], does not con-
tribute to unfavourable fibrin clot properties in this patient 
group.
This study has several limitations. Although the study 
was adequately powered, the number of patients with venous 
ulcers was limited, however the prevalence of post-throm-
botic ulcers is low as shown in other studies [34, 35]. Our 
study was designed to assess fibrin clots in relation to PTS in 
patients below 70 years, free of severe thrombophilia, cancer 
or diabetes to avoid factors adversely affecting clot pheno-
type [22, 36, 37]. Our results cannot be easily extrapolated 
to those patient subsets. Molecular mechanisms underlying 
elevated risk of post-thrombotic ulcers in the presence of 
the prothrombotic clot phenotype were beyond the scope 
of the current study. It has been shown that decreased  Ks 
not only correlates with thromboembolic events, but also is 
associated with an elevated bleeding risk and, consequently, 
with disturbances in healing of mild skin injuries [38]. This 
observation may explain at least in part the persistence of 
venous ulcers in individuals characterised by unfavourable 
fibrin clot phenotype.
The current study demonstrates that patients who develop 
venous ulcers following DVT produce dense and lysis-resist-
ant fibrin clots. It might be speculated that measurement of 
clot permeability and CLT might be useful in identifying 
DVT patients at high risk of post-thrombotic ulcers. How to 
reduce this risk should be a subject of further investigation.
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